Jackson Creek Investment Advisors LLC acquired a new stake in Envista Holdings Corporation (NYSE:NVST – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 66,630 shares of the company’s stock, valued at approximately $1,447,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Holocene Advisors LP acquired a new stake in Envista during the second quarter valued at approximately $43,936,000. Alliancebernstein L.P. lifted its stake in Envista by 34.0% during the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after purchasing an additional 1,547,656 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in Envista during the third quarter valued at approximately $24,260,000. Integral Health Asset Management LLC acquired a new stake in Envista during the third quarter valued at approximately $11,204,000. Finally, Massachusetts Financial Services Co. MA lifted its stake in Envista by 15.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,349,874 shares of the company’s stock valued at $72,726,000 after purchasing an additional 444,725 shares during the last quarter.
Envista Stock Down 0.8%
Shares of NYSE:NVST opened at $23.32 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.44. The company has a market cap of $3.80 billion, a PE ratio of 56.89, a price-to-earnings-growth ratio of 1.47 and a beta of 0.92. Envista Holdings Corporation has a 52 week low of $17.78 and a 52 week high of $30.42. The firm has a 50 day simple moving average of $25.47 and a 200 day simple moving average of $24.41.
Analyst Ratings Changes
Several analysts recently commented on the stock. JPMorgan Chase & Co. increased their target price on shares of Envista from $26.00 to $29.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Piper Sandler reissued a “neutral” rating and set a $25.00 target price (up from $21.00) on shares of Envista in a research note on Friday, February 6th. Citigroup assumed coverage on shares of Envista in a research note on Wednesday, April 15th. They set a “neutral” rating and a $29.00 target price for the company. Wall Street Zen lowered shares of Envista from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley increased their target price on shares of Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a research note on Friday, April 24th. Six research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Envista has a consensus rating of “Hold” and an average target price of $28.83.
View Our Latest Stock Analysis on NVST
About Envista
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Read More
- Five stocks we like better than Envista
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
